Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Urinary Tract Calculi III: Medical Management

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lattice Radiation Therapy Delays Progression and Extends Survival for Dogs with Macroscopic Soft Tissue Sarcoma.

Radiation research·2026

Same author

Investigating the Toxicity and Biodistribution of Boron-loaded Liposomes in Canine and Feline Models.

Radiation research·2026

Same author

A virtual-live hybrid training session is feasible with positive impact on colonoscopy key performance indicators amongst trainees.

Acta gastro-enterologica Belgica·2026

Same author

Colonic polypectomy in 2024: hot or cold?

Acta gastro-enterologica Belgica·2025

Same author

Solitary osseous plasmacytomas in dogs: 13 cases (2004-2019).

The Journal of small animal practice·2021

Same author

MRI of CNS lymphoma with choroid plexus involvement in five dogs and one cat.

The Journal of small animal practice·2021

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.

C J Henry¹, B K Flesner¹, S A Bechtel¹

¹College of Veterinary Medicine, University of Missouri, Columbia, MO.

Journal of Veterinary Internal Medicine

|October 29, 2017

Summary

Tavocept significantly reduced cisplatin-induced nephrotoxicity and diuresis time in dogs with bladder cancer. While survival was similar to historical controls, the response rate was lower, warranting further investigation.

Keywords:

Chemoprotectant Neoplasia Nephrotoxicity Urogenital

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

Related Experiment Videos

Last Updated: Jun 24, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

Area of Science:

Veterinary Oncology
Comparative Oncology
Cancer Chemotherapy

Background:

Transitional cell carcinoma is the most common canine bladder cancer.
Cisplatin and piroxicam offer superior response rates but cause significant nephrotoxicity.
Tavocept, a chemoprotectant, has shown promise in mitigating cisplatin toxicity in humans.

Purpose of the Study:

To evaluate Tavocept's efficacy in reducing diuresis volume and time during cisplatin/piroxicam treatment for canine bladder cancer.
To assess the safety and tolerability of this combination protocol.
To compare response rates and survival times with historical data.

Main Methods:

Fourteen dogs with transitional cell carcinoma received Tavocept, cisplatin, and piroxicam with a shortened diuresis protocol.
Tumor volume was assessed via CT scans.
Nephrotoxicity was monitored through serial biochemical analyses for azotemia.

Main Results:

The infusion/diuresis time was reduced to 90 minutes for all dogs.
A significantly lower frequency of nephrotoxicity (azotemia) was observed compared to historical controls (P = 0.0406).
The overall response rate was 27%, and median survival time was comparable to historical controls.

Conclusions:

Tavocept effectively decreased diuresis time and reduced cisplatin-induced azotemia in dogs.
While survival outcomes were similar, the response rate was inferior to historical controls.
Further research into Tavocept's use in other platinum-agent-susceptible tumors is recommended.